Spectral AI CEO, Wensheng Fan, to Participate in AI Healthcare Panel at Accelerate Health Conference
05 Outubro 2023 - 9:00AM
Spectral AI, Inc. (Nasdaq: MDAI; MDAIW) (“Spectral AI” or
the “Company”), an artificial intelligence (AI) company
focused on medical diagnostics for faster and more accurate
treatment decisions in wound care, today announced the
participation of Wensheng Fan, CEO of Spectral AI, as a panelist in
the upcoming Accelerate Health: Pioneering Solutions for a
Healthier Society Conference. The conference, presented by Worth
Media and KPMG, will take place on October 11, 2023, at 8:00 am, at
KPMG's Boston office, located at Two Financial Center, 60 South St,
Boston, MA 02111.
The second edition of the Accelerate Health
Conference is a one-day event dedicated to exploring the
transformative impact of technology on the healthcare industry. It
brings together prominent figures from the fields of health and
life sciences, including innovators, payers, providers,
pharmaceutical executives, and tech entrepreneurs. The conference
aims to foster conversation on how technological advancements can
drive progress towards a healthier society.
The panel discussion titled "AI's Medical
Odyssey: How Technology Is Rewriting the Healthcare Story," will
feature Wensheng Fan alongside prominent industry leaders such as
Simon Arkell, CEO of Synthetica Bio, and Fergus Fleming, CEO of
Renalytix. The distinguished panel will explore the profound impact
of artificial intelligence on the healthcare landscape, emphasizing
its transformative potential in revolutionizing healthcare
practices and improving patient outcomes.
With an anticipated gathering of nearly 200
executives, the Accelerate Health Conference presents an
exceptional platform for fostering networking and collaboration
among professionals in both the technology and healthcare
sectors.
For more information about the Accelerate Health
Conference and its agenda, please visit
https://techonomy.com/event/accelerate-health-pioneering-solutions
About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive
AI company focused on medical diagnostics for faster and more
accurate treatment decisions in wound care, with initial
applications involving patients with burns and diabetic foot
ulcers. The Company is working to revolutionize the management of
wound care by “Seeing the Unknown®” with its DeepView® System.
DeepView® is a predictive diagnostic device that offers
clinicians an objective and immediate assessment of a wound’s
healing potential prior to treatment or other medical intervention.
With algorithm-driven results and a goal of substantially exceeding
the current standard of care in the future, DeepView® is
expected to provide faster and more accurate treatment insight
towards value care by improving patient outcomes and reducing
healthcare costs. For more information about DeepView®,
visit www.spectral-ai.com.
Forward Looking
StatementsCertain statements made in this release are
“forward looking statements” within the meaning of the “safe
harbor” provisions of the United States Private Securities
Litigation Reform Act of 1995, including statements regarding the
Company’s strategy, plans, objectives, initiatives and financial
outlook. When used in this press release, the words “estimates,”
“projected,” “expects,” “anticipates,” “forecasts,” “plans,”
“intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,”
“propose” and variations of these words or similar expressions (or
the negative versions of such words or expressions) are intended to
identify forward-looking statements.
These forward-looking statements are not
guarantees of future performance, conditions or results, and
involve a number of known and unknown risks, uncertainties,
assumptions and other important factors, many of which are outside
Company’s control, that could cause actual results or outcomes to
differ materially from those discussed in the forward-looking
statements. As such, readers are cautioned not to place undue
reliance on any forward-looking statements.
Investors should carefully consider the
foregoing factors and the other risks and uncertainties described
in the “Risk Factors” sections of the Company’s filings with the
SEC, including the Registration Statement and the other documents
filed by the Company. These filings identify and address other
important risks and uncertainties that could cause actual events
and results to differ materially from those contained in the
forward-looking statements.
Contacts:
Investors:Spectral AIChristine
Marks VP Marketing and Commercialization
ir@spectral-ai.com
The Equity GroupDevin SullivanManaging
Directordsullivan@equityny.com
Conor RodriguezAnalystcrodriguez@equityny.com
Media:Russo PartnersDavid
SchullRusso Partners(858)
717-2310david.schull@russopartnersllc.com
Guillermo Ruiz, M.D., Ph.D.Russo Partners(646)
218-4604guillermo.ruiz@russopartnersllc.com
Spectral AI (NASDAQ:MDAI)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Spectral AI (NASDAQ:MDAI)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024